|

Afatinib Clinical Trials

7 actively recruiting trials across 1 location

▼ -3 trials since June 2026

Also known as: 30mg po qd, Gilotrif(Boehringer-Ingelheim), Gilotrif™, Giotrif, Targeted therapy

Pipeline

Early 1: 1Phase 1: 2Phase 2: 2Phase 1/2: 2

Top Sponsors

  • West China Hospital1
  • The Netherlands Cancer Institute1
  • Shanghai Jiao Tong University School of Medicine1
  • Massachusetts General Hospital1
  • Jeeyun Lee1

Indications

  • Cancer7
  • Lysogenic HSV Virus1
  • Neoplasia1
  • Tumors1
  • Fanconi Anemia1

Other6 trials

A Clinical Study on Neoadjuvant Treatment of Resectable Head and Neck Squamous Carcinoma With Immune-targeted Therapy and Lysogenic HSV Virus
Phase 1
Afatinib in Patients With Fanconi Anemia (FA) and Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)
Phase 1/2
Pilot Trial for Treatment of Recurrent Glioblastoma
Early 1
Target Therapy With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNA
Phase 2
The Drug Rediscovery Protocol (DRUP Trial)
Phase 2
Trastuzumab Deruxtecan(T-DXd) and Afatinib Combination in HER2-low Advanced Gastric Cancer
Phase 1/2

Boston, Massachusetts1 trial

Pemigatinib + Afatinib in Advanced Refractory Solid Tumors

Massachusetts General Hospital

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.